Disposition of 1750 shares by Ragosa Mark of Kiniksa Pharmaceuticals subject to Rule 16b-3

KNSA Stock  USD 20.30  0.30  1.50%   
About 50% of Kiniksa Pharmaceuticals' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Kiniksa Pharmaceuticals suggests that some traders are interested. The current market sentiment, together with Kiniksa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Kiniksa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Kiniksa Pharmaceuticals Officer Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3

Read at macroaxis.com
Kiniksa insider trading alert for disposition of restricted share unit by Ragosa Mark, Officer: Chief Financial Officer, on 7th of January 2025. This event was filed by Kiniksa Pharmaceuticals with SEC on 2024-09-01. Statement of changes in beneficial ownership - SEC Form 4

Kiniksa Pharmaceuticals Fundamental Analysis

We analyze Kiniksa Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiniksa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiniksa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Price To Earnings To Growth

Price To Earnings To Growth Comparative Analysis

Kiniksa Pharmaceuticals is currently under evaluation in price to earnings to growth category among its peers. PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

Kiniksa Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kiniksa Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Kiniksa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiniksa Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Kiniksa Pharmaceuticals Related Equities

REPLReplimune   2.95   
0%
27.0%
GPCRStructure Therapeutics   0.52   
4.0%
0%
NVCTNuvectis Pharma   0.96   
8.0%
0%
KRONKronos Bio   1.00   
9.0%
0%
DAWNDay One   1.61   
15.0%
0%
COGTCogent Biosciences   1.70   
15.0%
0%
BOLTBolt Biotherapeutics   1.72   
16.0%
0%
NUVLNuvalent   2.33   
21.0%
0%
PHATPhathom Pharmaceuticals   3.47   
32.0%
0%
CGEMCullinan Oncology   3.72   
34.0%
0%
CHRSCoherus BioSciences   3.82   
35.0%
0%
LRMRLarimar Therapeutics   4.29   
40.0%
0%
SPROSpero Therapeutics   4.76   
44.0%
0%
KURAKura Oncology   4.77   
44.0%
0%
GOSSGossamer Bio   5.41   
50.0%
0%
ACLXArcellx   6.22   
58.0%
0%
LYRALyra Therapeutics   9.09   
84.0%
0%
VTYXVentyx Biosciences   10.71   
100.0%
0%

Complementary Tools for Kiniksa Stock analysis

When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Bonds Directory
Find actively traded corporate debentures issued by US companies